RBC Capital Reiterates Sector Perform on Neurocrine Biosciences, Raises Price Target to $108
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating on Neurocrine Biosciences (NASDAQ:NBIX) and raised the price target from $106 to $108.
June 05, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating on Neurocrine Biosciences and raised the price target from $106 to $108.
The news of RBC Capital reiterating a Sector Perform rating and raising the price target for Neurocrine Biosciences (NBIX) is directly related to the company. However, the change in price target is relatively small, and the rating remains the same, indicating a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100